Disease Biology

2:20
Venetoclax-resistance conferring mutation in CLL identified
Piers Blombery
1:01
Metabolic profiling of the leukemia stem cell
Giovanni Martinelli
1:33
PALB2 predicts poor prognosis in AML and indicates potential targets for synthetic lethal therapies
Giovanni Martinelli
2:20
Telomere length can predict the outcome of FCR chemoimmunotherapy in CLL
Christopher Fegan
2:11
Telomere length as a prognostic tool in CLL: is FCR chemoimmunotherapy the right treatment?
Christopher Fegan
2:11
Mass spectrometry-flow cytometry study of IgM MGUS progression to Waldenström’s
Jonas Paludo
5:26
Specific BCL2 mutation confers resistance to venetoclax in progressive CLL
Piers Blombery
2:12
A step towards next-generation immune monitoring in multiple myeloma?
Bruno Paiva
3:27
Understanding myeloma disease dissemination: are CTCs responsible?
Bruno Paiva
2:02
Monoallelic TP53-mutated CLL patients show durable response to ibrutinib monotherapy
Carsten Niemann
1:43
Studying the genetics of CLL to prevent Richter’s transformation
Stephan Stilgenbauer
3:36
CLL-induced mitochondrial dysfunction in CD8+ T cells impedes CAR-T efficacy
Arnon Kater
2:04
Understanding risk factors for Ritcher’s transformation: addressing the unmet need
Carsten Niemann
5:29
CML-IT-MOS: clinical characteristics of CML patients not included in clinical trials
Giuseppe Saglio
1:50
Current ERIC research in the CLL genomics field
Richard Rosenquist
3:08
Resistance mechanisms in CLL
Richard Rosenquist
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals